Multidisciplinary treatment of patients with diabetes and hypertension: experience of a Brazilian center

Table 4 Patients who achieved treatment goals^a in visit 3 compared to those whom did not achieve (n = 162), Goiânia—GO

	Treatment goals in visit 3 Not achieved	Treatment goals in visit 3 Achieved	p value^b
N	151	11
Female	122 (80.8%)	8 (72.7%)	0.520
Age (years)	62.57 (± 11.54)	68.00 (± 10.15)	0.130
Total follow-up time (months)^c	60 (37–105)	64 (51–150)	0.210
Number of anti-HTN	2.81 (± 0.84)	3.00 (± 0.77)	0.460
ACE inhibitors/ARBs	141 (93.4%)	9 (81.8%)	0.160
Body mass index (kg/m²)	30.77 (5.61)	27.48 (3.86)	0.057
Insulin	33 (21.9%)	0 (0.0%)	0.082
Oral hypoglycemic agents	141 (93.4%)	9 (81.8%)	0.160
Aspirin	47 (31.1%)	5 (45.5%)	0.330
Statins	94 (62.3%)	4 (36.4%)	0.090
Cardiovascular event^d	48 (31.8%)	3 (27.3%)	0.760
Sedentary lifestyle	25 (16.6%)	1 (9.1%)	0.510
Smoke	5 (3.3%)	0 (0.0%)	0.540
Alcohol consumption	5 (3.3%)	0 (0.0%)	0.540
Treatment compliance	100 (66.7%)	11 (100.0%)	0.021
Predicted Framingham 10-year cardiovascular risk
Low	14 (9.3%)	1 (9.1%)	0.980
Intermediate	50 (33.1%)	5 (45.4%)	0.400
High	38 (25.2%)	2 (18.2%)	0.600
Very high	49 (32.4%)	3 (27.3%)	0.720

Values given in means (± SD) or n (%)
^aBlood pressure < 130 × 80 mmHg, LDL-cholesterol < 70 mg/dL, HbA1C < 7.0%
^bStatistically significant at α = 0.05
^cValues give in median and interquartile range
^dCardiovascular event—history of acute myocardial infarction, angina, cerebrovascular event, or revascularization

ISSN: 1758-5996